ImmuCell Corporation logo

ImmuCell Corporation(ICCC)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
2-STAR RATING
PASS
LAST CLOSE
$10.75
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ICCC

11/13/2026: ICCC (2-star) is currently NOT-A-BUY. Pass it for now.

ImmuCell Corporation is a specialized animal health biotechnology company that develops natural passive immunity and diagnostic products to enhance livestock productivity. Its primary operational strength stems from the established First Defense product line, which drives steady baseline revenues in neonatal calf care. The key investment growth story centers on expanding market penetration and advancing late-stage pipeline treatments like Re-Tain. However, the company faces notable risks, including high product concentration, intense competition from major pharmaceutical conglomerates, and regulatory execution uncertainties. The stock suits growth-oriented or speculative investors willing to navigate micro-cap volatility while monitoring clinical and commercial milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers niche biotechnology growth potential tied to new product adoption, though overall revenue scale remains relatively small.
Momentum investorStrong fit while signal remains positiveMomentum participants may target the stock during periods of favorable earnings reports or regulatory catalysts.
Value investorMixed fitValuation multiples can appear elevated relative to current earnings due to heavy reinvestment in pipeline drug development.
Dividend investorWeak fitImmuCell does not pay a dividend, prioritizing internal reinvestment over cash distributions.
Low-risk investorWeak fitMicro-cap biotechnology exposure introduces considerable stock price volatility and operational execution risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap stock liquidity can lead to sharp share price fluctuations on modest trading volume.
Valuation riskMedium / highThe stock's valuation is sensitive to shifts in profitability and clinical pipeline expectations.
Competition risk (animal health giants)HighWell-capitalized competitors possess greater resources to market alternative veterinary products.
Business qualityMediumImmuCell maintains proprietary technology and loyal customer niches, but operates with limited financial scale.
Dividend incomeLow / noneNo dividend is distributed to shareholders.
Execution riskHighSuccess depends heavily on regulatory approvals and commercial scaling of new product candidates like Re-Tain.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 97.73M USD
Price to earnings Ratio 56.58
1Y Target Price 14
Price to earnings Ratio 56.58
1Y Target Price 14
Volume (30-day avg) 8.9K shares
Beta 0.62
52 Weeks Range 4.52 - 12.10
Updated Date 11/15/2026
52 Weeks Range 4.52 - 12.10
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.19

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit 5.53%
Avg. Invested days 37
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 2.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ICCC receives a 3-star rating, supported by solid company fundamentals. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
ICCC has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+51.8%) is partially offset by soft cash generation (FCF margin 4.4%), moderate revenue growth (+4.3%), weak profitability (net margin -3.8%).

Financial Health Rating

★★★★★
ICCC's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 30.5%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is ICCC's strongest growth driver at +1236.0% FY2025 versus FY2024 (strong, 5 stars). By comparison, earnings growth (+51.8%, strong) is also strong, while revenue growth (+4.3%, moderate) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 20.4% and approximately 66.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 32.09% supports management-shareholder alignment.

Top 5 Institutional Investors

Vanguard Capital Management, LLC 2.95%
Morgan Stanley - Brokerage Accounts 2.57%
Renaissance Technologies Corp 1.91%
Cresset Asset Management, LLC 1.49%
Geode Capital Management, LLC 0.79%

Unit Economics (Per $1K Revenue)

★★★★★
ICCC generates approximately $414 of gross profit, $60 of operating income, and $44 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Soft margins explain the 2-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -1.12% (Tax Credit)

Quantitative Style Profile

★★★★★
ICCC has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Scours Segment (First Defense)Sales of orally delivered passive antibody products designed to prevent scours in newborn dairy and beef calves.This is the primary engine generating the majority of the company's current revenues.
Mastitis Segment (CMT & Diagnostics)Sales of the California Mastitis Test reagents and equipment for on-farm milk quality testing.Provides a steady complementary revenue stream while newer treatments are developed.
Geographic MarketsDistribution across the United States and international dairy markets primarily via veterinary and agricultural distributors.Exposes the business primarily to domestic dairy and beef farm economic conditions.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-12
When After Market
Estimate -
Actual 0.1

Profitability

Profit Margin 2.57%
Operating Margin (TTM) 15.21%

Management Effectiveness

Return on Assets (TTM) 6.25%
Return on Equity (TTM) 2.57%

Valuation

Trailing PE 56.58
Forward PE -
Enterprise Value 101.83M
Price to Sales(TTM) 3.19
Enterprise Value 101.83M
Price to Sales(TTM) 3.19
Enterprise Value to Revenue 3.07
Enterprise Value to EBITDA 22.78
Shares Outstanding 9.09M
Shares Floating 6.03M
Shares Outstanding 9.09M
Shares Floating 6.03M
Percent Insiders 32.09
Percent Institutions 20.39

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.